Efficacy of tirzepatide in glycemic control and weight management in adults with type 2 diabetes: a systematic review and meta-analysis of real-world studies

Treating adults with type 2 diabetes with tirzepatide in real-world settings was associated with an average HbA1c reduction of 0.91% and weight loss of 9.7 kg across 13 studies. Most users (64%) reached an HbA1c below 7%, and tirzepatide lowered HbA1c and body weight more than control. The evidence is observational and had moderate to serious risk of bias.

Meta-analysis — Systematic review and meta-analysis. Population: Adults with type 2 diabetes in real-world studies. Sample size: 89 296. Follow-up: 3-18 months. Interventions: Tirzepatide. Cited by 1 other paper.

Across 13 real-world studies (N = 89 296; duration 3-18 months) with moderate to serious bias, tirzepatide was associated with a mean HbA1c reduction of 0.91% (95% CI: -1.04 to -0.79), weight loss of 9.7 kg (95% CI: -14.05 to -5.35), and BMI decrease of 2.09 kg/m2 (95% CI: -3.27 to -0.92). Overall, 64% of tirzepatide users reached HbA1c <7%. Tirzepatide lowered HbA1c more than control (MD -0.38%; 95% CI: -0.44 to -0.33) and body weight more than control (MD -6.27 kg; 95% CI: -9.22 to -0.33). Among users, 47%, 23%, 9%, and 4% lost ≥5%, ≥10%, ≥15%, and ≥20% of baseline weight, respectively.

This paper aggregates real-world evidence on tirzepatide for HbA1c lowering and weight management in type 2 diabetes, providing effect sizes and responder rates that researchers can compare with clinical trial data. It does not establish tirzepatide's relative effectiveness against specific diabetes drugs, dose-response relationships, or safety outcomes in routine care.

Key findings

• Across 13 real-world studies, tirzepatide was associated with a mean HbA1c reduction of 0.91% (95% CI: -1.04 to -0.79).
• Mean weight loss was 9.7 kg (95% CI: -14.05 to -5.35) and BMI decreased by 2.09 kg/m2 (95% CI: -3.27 to -0.92).
• 64% of tirzepatide users achieved HbA1c <7%.
• Compared with control, tirzepatide lowered HbA1c by a mean difference of -0.38% (95% CI: -0.44 to -0.33) and body weight by -6.27 kg (95% CI: -9.22 to -0.33).
• Weight-loss thresholds were reached by 47%, 23%, 9%, and 4% of users for ≥5%, ≥10%, ≥15%, and ≥20% baseline weight loss, respectively.

Limitations

• The authors report that the included real-world studies had moderate to serious risk of bias.
• Observational real-world designs are susceptible to residual confounding and treatment selection bias.
• The abstract does not specify the control comparator or tirzepatide dosing.
• The 3-18 month duration range limits conclusions about long-term effects.

The record

• Journal: Postgraduate medical journal 102(1208): 486-496
• Published: 2026-05-20
• PMID: 41536268 — DOI: 10.1093/postmj/qgaf238
• MeSH terms: Humans, Diabetes Mellitus, Type 2, Weight Loss, Blood Glucose, Hypoglycemic Agents, Treatment Outcome, Glycemic Control, Glycated Hemoglobin, Tirzepatide
• Author countries: Bangladesh, India, United Kingdom

Peptide profiles: Tirzepatide.

All indexed evidence: Tirzepatide trials & papers.

Related studies: Peripheral nerve complications from medications utilised for weight loss: a systematic…, Incretin-Based Therapies in Doxorubicin-Induced Cardiotoxicity: A Systematic Review of…, Effects of GLP-1 Receptor Agonists and Dual GIP/GLP-1 Receptor Agonists on Inflammatory…, Comparative effects of drugs for adults with overweight or obesity: systematic review….